Form 4: Tenaya Therapeutics Director Jeffrey T. Walsh Granted 107,400 Stock Options

Jeffrey T. Walsh, a Director at Tenaya Therapeutics, Inc., was granted 107,400 stock options with an exercise price of $0.4444 per share, vesting over approximately one year.

Summary

• Jeffrey T. Walsh, a Director of Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options.
• The options have an exercise price of $0.4444 per share.
• The grant date for these options was May 29, 2025.
• The options will vest in full on May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date.
• Vesting is subject to Mr. Walsh continuing to be a service provider to Tenaya Therapeutics through the applicable vesting date.
• The options were granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• The expiration date for these options is May 28, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates alignment of interests between a director and shareholders through equity compensation, which is a standard and generally well-regarded practice. There are no negative operational or financial implications directly from this filing.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the company's stock price increases.
• The options are part of an existing equity incentive plan, indicating a structured approach to executive and director compensation.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although this is common with equity compensation plans.

Risks

• The value of the stock options is directly tied to the future performance of Tenaya Therapeutics' stock price; if the stock price does not exceed the exercise price of $0.4444, the options may expire worthless.
• Continued service is required for vesting, meaning Mr. Walsh would forfeit unvested options if his service to the company ceases before the vesting date.

Future Outlook

NA

Industry Context

This transaction is a routine equity compensation grant to a director, common practice across the biotechnology and pharmaceutical industries to attract and retain talent and align their interests with long-term company performance.

Stakeholder Impact

• Shareholders: Potential minor dilution if and when the options are exercised, but also potential benefit from improved director alignment with company performance.
• Employees: No direct impact on general employees from this specific director grant.

Next Steps

• The stock options will vest on May 29, 2026, or earlier, subject to continued service.
• Upon vesting, Mr. Walsh will have the right to exercise the options to purchase common stock at the specified exercise price until the expiration date.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Stock Options, Insider Transaction, SEC Form 4, Equity Incentive Plan, Director Compensation, Biotechnology, Pharmaceuticals